Vimalanand S Prabhu, Srujitha Marupuru, Kathleen M McClain, Ke Meng, Vy Tran, Kirti Mirchandani, Robert Orlowski, Robin Meng, Christian Marth, Angela K Green, Vicky Makker
{"title":"Real‑World Treatment Patterns in Endometrial Cancer in the Post-Immune Checkpoint Inhibitor and Post-Platinum-Based Chemotherapy Setting in the United States.","authors":"Vimalanand S Prabhu, Srujitha Marupuru, Kathleen M McClain, Ke Meng, Vy Tran, Kirti Mirchandani, Robert Orlowski, Robin Meng, Christian Marth, Angela K Green, Vicky Makker","doi":"10.1007/s12325-026-03830-x","DOIUrl":"https://doi.org/10.1007/s12325-026-03830-x","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICI), either following or in combination with platinum chemotherapy (PT), are routinely used to treat endometrial cancer (EC). Subsequently, a post-ICI and post-PT patient population is emerging with no approved therapy or guideline-recommended treatment approach for this setting. As novel therapies are being explored, it is critical to understand the patient characteristics and real-world treatment patterns in this setting.</p><p><strong>Methods: </strong>This retrospective observational study used de-identified electronic health record data from the Flatiron Health database (2013-2026). Adult women with EC who had prior exposure to both ICI and PT and subsequently initiated a new regimen (the index line of therapy [LOT]) were included. The results were stratified by mismatch repair and microsatellite instability (MMR/MSI) status, and treatment patterns were summarized descriptively.</p><p><strong>Results: </strong>A total of 564 women met the selection criteria, including 34 (6.0%) treated in the first LOT, 188 (33.3%) in the second LOT, 189 (33.5%) in the third LOT, and 153 (27.1%) in the fourth LOT or later. Among patients with deficient MMR/MSI-High (dMMR/MSI-H) tumors, post-ICI and post-PT regimens usually included hormonal therapy (18.0%) and ICI monotherapy (14.0%). Among patients with proficient MMR and microsatellite stable (pMMR/MSS) tumors, chemotherapy monotherapy (25.7%) and ICI plus tyrosine kinase inhibitor combinations (11.9%) were most frequent. A total of 228 patients (40.4%) received an ICI-containing regimen at the index LOT or a subsequent line, of whom 179 (78.5%) received a pembrolizumab-containing regimen, 21 (9.2%) a dostarlimab-containing regimen, and 28 (12.3%) other ICI-containing regimens.</p><p><strong>Conclusions: </strong>In EC, the post-ICI and post-PT patient population is growing, particularly in the second LOT and earlier settings. Treatment following ICI and PT exposure in EC was highly variable, with no dominant regimen identified regardless of MMR/MSI status.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mechanisms Behind the Disease: Understanding the Role of APRIL in IgAN Pathogenesis: A Podcast.","authors":"Lama Abdelnour, Abdallah Geara, Fahmeedah Kamal","doi":"10.1007/s12325-026-03840-9","DOIUrl":"https://doi.org/10.1007/s12325-026-03840-9","url":null,"abstract":"<p><p>This podcast provides an overview of immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide and a progressive, immune-mediated chronic kidney disease (CKD) often diagnosed in early to mid-adulthood. Patients face heterogeneous presentations ranging from asymptomatic disease to proteinuria and hematuria leading to rapid loss of kidney function, with many progressing to kidney failure within a decade. Beyond renal effects, IgAN imposes substantial quality-of-life burdens, particularly affecting individuals of childbearing potential. The pathogenesis of IgAN is best explained by the four-hit process involving the overproduction of galactose-deficient immunoglobulin A1 (Gd-IgA1), development of anti-Gd-IgA1 autoantibodies, immune complex formation, and mesangial deposition of immune complexes, leading to complement activation and glomerular injury. Central to this process is dysregulated B cell activation, differentiation, and immunoglobulin class switching. A proliferation-inducing ligand (APRIL), a member of the tumor necrosis factor superfamily, promotes pathogenic IgA1 production through plasma cell survival and IgA class switching. Genetic, preclinical, and clinical evidence implicates APRIL as a key driver of IgAN pathophysiology. Management strategies such as using renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors focus on supportive care and mitigation of generic CKD drivers but do not directly address upstream immune mechanisms, leaving many patients at risk for irreversible nephron loss. With the 2025 Kidney Disease: Improving Global Outcomes guidelines, the treatment of IgAN is evolving toward earlier, proactive management that simultaneously targets IgA immune complex-mediated injury and the long-term consequences of CKD. Emerging insights into APRIL-driven pathways support the development of targeted therapies that may selectively reduce pathogenic IgA production while preserving protective immune function, offering a promising strategy to address the underlying disease mechanism and improve long-term outcomes and quality of life in patients with IgAN.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rakesh Jain, Hemangi R Panchmatia, Alejandro G Hughes, Michael J Doane, Hara E Oyedeji, Andrew J Cutler
{"title":"Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Bipolar I Disorder.","authors":"Rakesh Jain, Hemangi R Panchmatia, Alejandro G Hughes, Michael J Doane, Hara E Oyedeji, Andrew J Cutler","doi":"10.1007/s12325-026-03807-w","DOIUrl":"https://doi.org/10.1007/s12325-026-03807-w","url":null,"abstract":"<p><strong>Introduction: </strong>This real-world data analysis examined healthcare resource utilization (HCRU) among patients with bipolar I disorder (BD-I) in the 12 months before and after initiating a combination of olanzapine and samidorphan (OLZ/SAM).</p><p><strong>Methods: </strong>This retrospective analysis used administrative claims data (October 18, 2020-December 31, 2023) from the Komodo Healthcare Map. Eligibility criteria included age ≥ 18 years and continuous enrollment in medical and pharmacy benefits ≥ 12 months before (baseline) and after (follow-up) initiating OLZ/SAM. Comparisons between baseline and follow-up included inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average number of IP days/patient. A subgroup analysis of patients receiving OLZ/SAM for the full 12-month follow-up period was conducted.</p><p><strong>Results: </strong>Overall, 1004 patients with BD-I who initiated OLZ/SAM were included. Mean (SD) age was 39.0 (12.5) years; 691 (68.8%) were female. Mean (SD) persistence was 173.7 (139.9) days. Overall, 300 (29.9%) patients received continuous OLZ/SAM treatment for the full 12-month follow-up period. Proportions of patients with ≥ 1 all-cause, mental health-related, or BD-I-related IP admission or ED visit between baseline and follow-up were significantly reduced (range - 16.4% to - 42.1%; all P < 0.001), as were mean numbers of IP days/patient (range - 3.9 to - 4.6 days; all P < 0.001). Proportions of patients with ≥ 1 OP visit were similar before and after starting OLZ/SAM, indicating that patients continued receiving OP care. Significant reductions in IP admissions and ED visits were also observed in patients receiving OLZ/SAM treatment for the entire 12-month follow-up period; these reductions were observed to be larger than those observed in the full cohort.</p><p><strong>Conclusion: </strong>Among patients with BD-I, initiating OLZ/SAM was associated with significant and clinically meaningful reductions in acute care HCRU compared with baseline. Larger reductions in acute HCRU were observed among patients with greater treatment persistence. Video abstract available for this article. Supplementary file1 (mp4 225 KB).</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew J Cutler, Hemangi R Panchmatia, Alejandro G Hughes, Michael J Doane, Hara E Oyedeji, Rakesh Jain
{"title":"Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Schizophrenia.","authors":"Andrew J Cutler, Hemangi R Panchmatia, Alejandro G Hughes, Michael J Doane, Hara E Oyedeji, Rakesh Jain","doi":"10.1007/s12325-026-03831-w","DOIUrl":"https://doi.org/10.1007/s12325-026-03831-w","url":null,"abstract":"<p><strong>Introduction: </strong>This study used real-world data to examine changes in healthcare resource utilization (HCRU) among patients with schizophrenia in the 12 months after initiating the combination of olanzapine and samidorphan (OLZ/SAM).</p><p><strong>Methods: </strong>This retrospective analysis used administrative claims data (October 18, 2020, to December 31, 2023) from the Komodo Healthcare Map. Adults with schizophrenia and continuous enrollment ≥ 12 months before (baseline) and after (follow-up) initiating OLZ/SAM were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of IP days/patient were compared between baseline and follow-up. A subgroup analysis of patients receiving OLZ/SAM treatment for the full 12-month follow-up was conducted.</p><p><strong>Results: </strong>A total of 1287 patients with schizophrenia initiating OLZ/SAM were included. Mean (SD) age was 38.8 (13.0) years; 53% were male. Patients were persistent for a mean (SD) of 196.6 (144.6) days. Overall, 481 (37.4%) patients received continuous OLZ/SAM treatment for the full 12-month follow-up. Proportions of patients with ≥ 1 all-cause, mental health-related, or schizophrenia-related IP admission or ED visit significantly decreased between baseline and follow-up (range - 13.0% to - 27.3%; all P < 0.001). Average numbers of all-cause, mental health-related, and schizophrenia-related inpatient days per patient decreased significantly (range - 5.2 to - 5.5 days; all P < 0.001). Proportions of patients with ≥ 1 OP visit were similar during baseline and follow-up, indicating that patients continued receiving outpatient care. Significant reductions in IP admissions and ED visits were also observed in patients receiving OLZ/SAM treatment for the full 12-month follow-up and were larger than those observed in the full cohort.</p><p><strong>Conclusion: </strong>Among patients with schizophrenia, initiating OLZ/SAM was associated with significant and clinically meaningful reductions in acute HCRU compared with baseline. Larger reductions in acute care HCRU were observed among patients who received continuous OLZ/SAM treatment throughout the 12-month follow-up period. A video abstract summarizing the study methods, results, and clinical implications is available in the online version of this article. Supplementary file1 (MP4 83203 kb).</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alden R Smith, Aimee D Shu, Lærke Clement Freiberg, Bart Degreve, Wahidullah Noori, Mihaela Musat, Nishant Mehra, Ben Mayer, Alberto Vidal-Diez, Hoora Moradian
{"title":"Epidemiology, Complications, and Management of Complications of Achondroplasia: A Systematic Literature Review and Meta-analysis.","authors":"Alden R Smith, Aimee D Shu, Lærke Clement Freiberg, Bart Degreve, Wahidullah Noori, Mihaela Musat, Nishant Mehra, Ben Mayer, Alberto Vidal-Diez, Hoora Moradian","doi":"10.1007/s12325-026-03838-3","DOIUrl":"https://doi.org/10.1007/s12325-026-03838-3","url":null,"abstract":"<p><strong>Introduction: </strong>Achondroplasia is a rare genetic condition associated with considerable clinical burden. This study examined the clinical burden of achondroplasia, including epidemiology, condition complications and their management, and the estimated prevalence of common complications.</p><p><strong>Methods: </strong>A systematic literature review (SLR) was conducted (September 2025) to identify articles published from 2011. As a result of heterogeneity across studies, meta-analyses of complication prevalence were restricted to pediatric and adolescent populations.</p><p><strong>Results: </strong>Overall, 200 studies were included. Forty-five studies reported epidemiological data; the prevalence of achondroplasia ranged from one to 67 per 100,000 births. The most common neurological complications were cervicomedullary compression/craniocervical junction stenosis (mean 34%; n = 13) and foramen magnum narrowing (FMN; mean 26%; n = 21). The top respiratory complications were sleep disordered breathing (SDB; mean 60%; n = 13) and obstructive sleep apnea (mean 48%; n = 27). Ear, nose, and throat (ENT) complications comprised ear infections (mean 40%; n = 12) and hearing impairment (mean 40%; n = 16). Common orthopedic complications included kyphosis (mean 43%; n = 22) and bowing of legs or genu varum (mean 39%; n = 7). The top complications among pediatric populations were SDB (mean 65% [95% confidence interval (CI) 36, 85]; n = 13) and FMN (mean 56% [37, 73]; n = 20). Cervicomedullary decompression (mean 11%; n = 22) was a more frequent treatment option for neurologic complications than suboccipital decompression (mean 19%; n = 3). Typical interventions included ENT procedures (mean 40%; n = 37) and surgery for orthopedic complications (mean 28%; n = 27). Twenty-six studies reported complications from limb-lengthening surgeries (mean age of treatment 6.2-16.9 years).</p><p><strong>Conclusion: </strong>This SLR and meta-analysis underscore the significant clinical burden related to complications and their management in individuals with achondroplasia. Prevalence estimates varied widely by geography, reflecting differences in data sources, case ascertainment, and reporting practices. The high frequency and severity of complications underscore the need for effective treatments to reduce complication burden and improve patient quality of life.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jolan Terner-Rosenthal, Robin Howard, Renee Shiota, Wiktor Stopka, Liz Turner
{"title":"Real-World Impact of Maralixibat Treatment on Concomitant Medication Use in USA-Based Patients with Alagille Syndrome and Cholestatic Pruritus: A Retrospective Analysis.","authors":"Jolan Terner-Rosenthal, Robin Howard, Renee Shiota, Wiktor Stopka, Liz Turner","doi":"10.1007/s12325-026-03844-5","DOIUrl":"https://doi.org/10.1007/s12325-026-03844-5","url":null,"abstract":"<p><strong>Introduction: </strong>Alagille syndrome (ALGS) is a rare cholestatic liver disease characterized by severe pruritus, with many patients also experiencing impaired growth, failure to thrive, and fat-soluble vitamin deficiencies. Patients often require multiple antipruritic medications to control pruritus and may also receive nutritional or vitamin supplements to address nutritional deficiencies and improve growth, leading to substantial polypharmacy burden. Maralixibat, a minimally absorbed ileal bile acid transporter inhibitor, is approved for the treatment of cholestatic pruritus in patients with ALGS ≥ 3 months of age in the USA and ≥ 2 months of age in the European Union (EU). This study evaluated real-world concomitant medication usage during long-term maralixibat treatment using pharmacy data from Mirum Access Plus, a single-source specialty pharmacy and education program for patients receiving maralixibat.</p><p><strong>Methods: </strong>A retrospective analysis was conducted using pharmacy data from the Mirum Access Plus program to evaluate concomitant medication trends for at least 2 years of potential use. Data were extracted on April 30, 2024, and included all patients in the USA who initiated maralixibat by April 1, 2022, and had not discontinued therapy.</p><p><strong>Results: </strong>This analysis included 178 patients with ALGS who received maralixibat. The median age at maralixibat initiation was 6 years. At the start of maralixibat treatment, patients were taking a median of two antipruritic medications and one nutritional or vitamin supplement. During maralixibat treatment, 43% of patients discontinued ≥ 1 concomitant medication, 21% discontinued ≥ 2 medications, and 8% discontinued ≥ 3 medications.</p><p><strong>Conclusions: </strong>These real-world results indicate treatment with maralixibat may reduce polypharmacy burden in patients with ALGS and their caregivers by enabling discontinuation of antipruritic medications and nutritional or vitamin supplements.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Craig Surman, Bruce Mehler, Ronna Fried, Antonio Pardo, R Eric Heidel, David S Fam, Jim Potenziano, Maura DiSalvo, Joseph Biederman
{"title":"Measuring the Effect of Amphetamine Extended-Release (DYANAVEL® XR) on Driving Performance in Young Adult Drivers with ADHD Using a Sophisticated Driving Simulation.","authors":"Craig Surman, Bruce Mehler, Ronna Fried, Antonio Pardo, R Eric Heidel, David S Fam, Jim Potenziano, Maura DiSalvo, Joseph Biederman","doi":"10.1007/s12325-026-03843-6","DOIUrl":"https://doi.org/10.1007/s12325-026-03843-6","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess the impact of treatment with a single amphetamine extended-release (Dyanavel® XR; DXR) 20 mg tablet on the driving performance of young adults with clinically established attention-deficit/hyperactivity disorder in a laboratory-based driving simulation environment.</p><p><strong>Methods: </strong>This single-center, randomized, double-blind, placebo-controlled study evaluated driving parameters during simulated drives undertaken predose, 45 min postdose, and 10 h postdose. The primary endpoints were safety-related simulator performance measures indexing proximity to a lead vehicle and braking response intensity across eight emergent conflict events per drive that required an attentive response by the driver. The driving simulation used what is believed to be a novel methodology among intervention trials that allowed inattentive drivers to come very close to a lead vehicle during a potential conflict event, but also adjusted lead vehicle dynamics so that a participant would not experience a simulated crash and thus influence their subsequent behavior. The key secondary endpoint was crash frequency during an event at the end of the third drive that did allow an inattentive driver to collide with a lead vehicle.</p><p><strong>Results: </strong>Forty-one male and female drivers aged 18-25 years completed the study: 21 participants in the DXR group and 20 in the placebo group. For DXR-treated participants with a complete evaluable data set (n = 17), statistically significant improvements in the minimum time to collision and mean highest braking intensity occurred across their three drives. These findings appeared as a positive trend when comparing the 45 min postdose drive with participants' baseline values and at statistically significant levels when comparing the 10 h postdose drive with baseline.</p><p><strong>Conclusion: </strong>Participants with attention-deficit/hyperactivity disorder who took a morning dose of DXR showed a pattern of behavior during simulated driving that was consistent with improved safety-margin behavior (greater time-to-collision) and less abrupt braking responses within the simulation context at 10 h postdose.</p><p><strong>Clinical trial registration: </strong>https://clinicaltrials.gov/study/NCT04027361 .</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial.","authors":"Prakash Kurmi, Manish Kumar Singh, Vishal Gupta, Chikkalingaiah Siddegowda, Jitendra Shukla, Sandip Gofne, Nilesh Lomte, Kaustubh Shendkar, Dinesh Gangwani, Surendra Kumar, Sandeep Gupta, Aravind Gultur Nagarajaiah, Amit Bhaskar, Prabhat Kumar, Arjun Baidya, Animesh Maiti, Ambanna Gowda, Jayesh Ambaliya, Balachandra Giriappa, Sunil Kumar Mahawar, Supriya Sonowal, Piyush Patel, Dipak Patil, Pravin Ghadge, Lalit Kumar Lakhwani, Suyog Mehta, Sadhna Joglekar","doi":"10.1007/s12325-026-03791-1","DOIUrl":"https://doi.org/10.1007/s12325-026-03791-1","url":null,"abstract":"<p><strong>Introduction: </strong>The global burden of type 2 diabetes mellitus (T2DM) is rapidly increasing, with India contributing significantly to the disease prevalence and associated economic burden. Despite metformin being the first-line therapy, many patients require combination treatment due to the progressive and multifactorial nature of T2DM. Fixed-dose combinations (FDCs) of drugs with complementary mechanisms may improve glycemic control, adherence, and treatment outcomes. This study has evaluated efficacy and safety of FDC of dapagliflozin (DAPA), glimepiride (GLIM), and metformin (MET) immediate release (IR) tablet versus co-administration of GLIM and MET tablets in patients with T2DM.</p><p><strong>Methods: </strong>This phase 3, randomized, open-label study included 536 Indian patients with T2DM [glycated hemoglobin (HbA1c) ≥ 8.0% and ≤ 11%], randomized (1:1:1:1) into four arms in primary treatment period (up to Week 16): FDC of DAPA + GLIM + MET [5 mg+1 mg+500 mg (Test 1)] or [5 mg+1 mg+1000 mg (Test 2)] twice-daily, or co-administration of GLIM and MET (1 mg and 500 mg) (Comparator 1) or GLIM and MET (1 mg and 1000 mg) (Comparator 2) twice-daily. Patients with HbA1c ≥ 7.0% at week 16 entered an uptitration period (increased GLIM dose to 2 mg; Weeks 16-28). Change in HbA1c from baseline to Week 16 was the primary endpoint.</p><p><strong>Results: </strong>At Week 16, least-square mean HbA1c reduction was significantly greater with Test 1 (- 2.17%) versus Comparator 1 (- 1.64%, p = 0.0047) and Test 2 (- 2.25%) versus Comparator 2 (- 1.72%, p < 0.0001). Similarly, the proportion of patients achieving HbA1c < 7.0% at Week 16 was significantly greater in Test 1 versus Comparator 1 and Test 2 versus Comparator 2 (p < 0.0002 and p < 0.0001, respectively). Reduction in HbA1c, fasting, and postprandial blood glucose from baseline to Weeks 12, 16, and 28 was significant in all arms. Overall, treatments were well tolerated.</p><p><strong>Conclusions: </strong>The FDC of DAPA + GLIM + MET IR tablet demonstrated superior glycemic control over co-administration of glimepiride and metformin and acceptable safety profile, making it an effective therapeutic option for T2DM management.</p><p><strong>Trial registration: </strong>Clinical Trials Registry India, CTRI/2022/06/043249.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Larry D Anderson, Sandhya Nair, Mi Jun Keng, Weili Sun, Eric Ammann, Diogo F Ramos, Fenny Ong, Marguerite O'Hara, Mary Slavcev, Niodita Gupta-Werner, Margaret Doyle, Wouter Plattel
{"title":"Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis.","authors":"Larry D Anderson, Sandhya Nair, Mi Jun Keng, Weili Sun, Eric Ammann, Diogo F Ramos, Fenny Ong, Marguerite O'Hara, Mary Slavcev, Niodita Gupta-Werner, Margaret Doyle, Wouter Plattel","doi":"10.1007/s12325-026-03832-9","DOIUrl":"https://doi.org/10.1007/s12325-026-03832-9","url":null,"abstract":"<p><strong>Introduction: </strong>In the phase 3 MajesTEC-3 study (NCT05083169), teclistamab with daratumumab (Tec-Dara) significantly improved progression-free and overall survival (PFS/OS) versus investigator's choice of standard-of-care daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy (pLOTs). Of the DPd/DVd patients, 85.5% (n = 253/296) of whom were refractory to an immunomodulatory drug (IMiD), 90.7% (n = 263/290) received IMiD-based DPd and 9.3% (n = 27/290) received proteasome inhibitor (PI)-based DVd. We leveraged individual patient-level data (IPD) from other pivotal trials to estimate and further substantiate comparative outcomes of Tec-Dara versus standard-of-care PI-based RRMM regimens: daratumumab/carfilzomib/dexamethasone (DKd; no current comparative evidence) and DVd (to support MajesTEC-3 findings). Inverse probability of treatment weighting (IPTW) was used to adjust for intertrial differences.</p><p><strong>Methods: </strong>IPD were available from MajesTEC-3 (Tec-Dara), CANDOR (NCT03158688; DKd), and CASTOR (NCT02136134; DVd). Patient characteristic imbalances were adjusted for using IPTW. Outcomes included PFS, OS, overall response rate (ORR), very good partial response or better (≥VGPR), and complete response or better (≥CR). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were estimated.</p><p><strong>Results: </strong>Following adjustment, key baseline characteristics were well balanced across cohorts. Tec-Dara was significantly associated with improved PFS versus DKd (HR 0.22; 95% CI 0.15-0.33; P < 0.001) and DVd (HR 0.11; 95% CI 0.07-0.17; P < 0.001); Tec-Dara was also significantly associated with improved OS (DKd: HR 0.40; 95% CI 0.26-0.61; DVd: HR 0.24; 95% CI 0.14-0.40; both P < 0.001). Patients demonstrated higher rates of ORR, ≥VGPR, and ≥CR with Tec-Dara versus DKd (RR 1.11, 1.33, and 2.84 respectively) and DVd (RR 1.10, 2.20, and 5.17).</p><p><strong>Conclusion: </strong>Tec-Dara demonstrated consistent PFS and OS benefits and deeper levels of response over DKd and DVd in patients with RRMM and 1-3 pLOTs. These results further support Tec-Dara as a new standard-of-care regimen for RRMM as early as second-line treatment.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: Pharmacokinetics, Safety, and Immunogenicity of DMB-3115, a Ustekinumab Biosimilar for Immune-Mediated Diseases, in Healthy Japanese Male Participants: A Randomized, Double-Blind, Single-Dose Study.","authors":"Hironori Konishi, Yuji Kumagai, Takeyuki Shindo, Michio Yagi, Takashi Eto, Rie Yazawa, Makoto Yono, Naoki Cho, Hideki Fushimi, Jun Morita","doi":"10.1007/s12325-026-03822-x","DOIUrl":"https://doi.org/10.1007/s12325-026-03822-x","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}